Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioShin Raises $60 Million to Bring Biohaven's Drugs to China

publication date: Sep 29, 2020

BioShin Limited of Shanghai raised $60 million in a Series A financing to develop Biohaven's clinical portfolio of neurological drugs in China. BioShin, a subsidiary of Biohaven, remains majority owned by Biohaven after the transaction. In Q4, BioShin will start a China/Korea Phase III trial of Nurtec™ ODT (rimegepant) for acute migraine. Also in Q4, it will begin a China arm of a global Phase III trial of troriluzole in Spinocerebellar Ataxia (SCA). The A round was led by OrbiMed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital